Last reviewed · How we verify

Lidocaine plus adrenaline

University of Santiago de Compostela · FDA-approved active Small molecule

Lidocaine blocks sodium channels to provide local anesthesia, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.

Lidocaine blocks sodium channels to provide local anesthesia, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity. Used for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia for minor surgical procedures.

At a glance

Generic nameLidocaine plus adrenaline
Also known asanaesthesia
SponsorUniversity of Santiago de Compostela
Drug classLocal anesthetic with vasopressor
TargetVoltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits sodium influx in nerve cell membranes, preventing depolarization and action potential propagation. Adrenaline is a sympathomimetic agent that causes vasoconstriction of local blood vessels, which slows the systemic absorption of lidocaine, extends its duration of action at the injection site, and reduces the risk of toxicity by maintaining local drug concentration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: